Esophageal squamous cell carcinoma
Conditions
Interventions
Observation Group of Esophageal Squamous cell carcinoma:None
Sponsors
Ningbo Medical Centre Lihuili Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with esophageal squamous cell carcinoma through gastroscopy biopsy and for whom tissue specimens were collected before treatment; 2. Patients with esophageal cancer who, based on the examination results, are clinically eligible for surgical resection before the operation; 3. Age >=18 years old, 4.0×10^9/L, absolute count of neutrophils (ANC) >=2.0×10^9/L, platelet count >100×10^9/L, hemoglobin >90g/L; 5. Be able to understand the situation of this research and sign the informed consent form. 6. Gastroscopy tissue and blood samples need to be collected at this center before treatment.
Exclusion criteria
Exclusion criteria: 1.History of autoimmune diseases; 2. Recently or currently taking hormones or immunosuppressants; 3. Have received immunotherapy in the past; 4. There is a history of severe hypersensitivity to antibody drugs in the past; 5. Have a history of or are currently suffering from chronic or recurrent autoimmune diseases; 6. Interstitial lung disease, pulmonary fibrosis, diverticulitis or systemic ulcerative gastrointestinal inflammation; 7. Confirmed history of congestive heart failure; 8. Angina pectoris that is poorly controlled by drug therapy; 9. Transmural myocardial infarction confirmed by electrocardiogram (ECG); 10. Poorly controlled hypertension; 11. Clinically significant heart valve disease; 12. Or high-risk uncontrollable arrhythmias; 13. Severe uncontrolled systemic intermittent diseases, such as active infections or poorly controlled diabetes; 14. Abnormal coagulation function, with a bleeding tendency, or currently undergoing thrombolytic or anticoagulant therapy; 15. Women with positive serum pregnancy tests or those who are breastfeeding, as well as men and women of childbearing age who are unwilling to take adequate contraceptive measures during the study of drug treatment; 16. Known immunodeficiency virus (HIV), hepatitis B virus (HB V), or hepatitis C virus (HCV); 17. Active infection or known HIV serological positivity; 18. Including HBV or HCV surface antigen positive (RNA); 19. Known to be allergic to any investigational drug; 20. Have a history of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation); 21. Those with peripheral nervous system disorders or a history of obvious mental disorders and central nervous system disorders; 22. Those who use anti-tumor drugs outside the study protocol in combination; 23. The researchers have determined that there are other factors that may lead to the forced termination of the study halfway, such as suffering from other serious diseases (including mental disorders) that require concurrent treatment, alcohol abuse, drug abuse, family or social factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Demographic characteristics: gender, age, weight, smoking history, drinking history, underlying diseases;General situation: Treatment medication plan, time for collecting tissue specimens and blood specimens;Laboratory inspection; | — |
Countries
China
Contacts
Public ContactNingning He
Ningbo Medical Center Lihuili Hospital
Outcome results
None listed